SCHEMBL3008395

SCHEMBL3008395

Cc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(F)c(Cl)c4)CC3)n2)cc1C

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 8/20 0.37
LPAR1 Q92633 1/20 0.35
LPAR2 Q9HBW0 1/20 0.35
SCN1A P35498 1/20 0.35
SCN8A Q9UQD0 1/20 0.35
DRD2 P14416 1/20 0.34
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
KCNH2 Q12809 1/20 0.34
TRPV1 Q8NER1 1/20 0.34
DNM1L O00429 2/20 0.33
CYP19A1 P11511 1/20 0.33
TP53 P04637 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
ALDH1A1 P00352 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009255 0.93 HTR2A (0.37) SOS1LPAR1LPAR2SCN1ASCN8A
SCHEMBL3011442 0.92 SCN1A (0.36) LPAR1LPAR2SCN1ASCN8ADNM1L
SCHEMBL3002470 0.91 TP53 (0.38) SOS1LPAR1LPAR2SCN1ASCN8A
SCHEMBL3014991 0.91 CACNA1G (0.36) SOS1LPAR1LPAR2SCN1ASCN8A
SCHEMBL3011357 0.90 L3MBTL1 (0.36) SOS1SCN1ASCN8ADRD2HTR2A
SCHEMBL3004485 0.90 HTR2A (0.36) SOS1LPAR1LPAR2SCN1ASCN8A
SCHEMBL3016860 0.90 L3MBTL1 (0.36) SOS1SCN1ASCN8ADRD2HTR2A
SCHEMBL3018344 0.90 HTR2A (0.41) LPAR1LPAR2SCN1ASCN8ADRD2
SCHEMBL3002167 0.90 MAPT (0.37) SCN1ASCN8ADRD2HTR2AHTR2C
SCHEMBL3020208 0.90 DRD2 (0.35) SOS1LPAR1LPAR2DRD2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SOS1 715/4885LPAR1 2066/4885LPAR2 1732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.